NASDAQ · Biotechnology · USD
FibroBiologics, Inc. (FBLG) Stock Analysis
FibroBiologics, Inc. (FBLG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
FBLG Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.90
- Previous Close
- $0.92
- Day's Range
- 0.90–1.00
- 52-Week Range
- 0.62–9.60
- Volume
- 127.36K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.74
Valuation
- Market Cap
- $7.03M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −5.01
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$18.65M
- Shares Outstanding
- 7.08M
- 1-Year Return
- −88.12%
Dividend and dates
- Avg Volume
- 210.53K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, FBLG closed at $0.99, −88.12% over 1 year.
FibroBiologics, Inc. (FBLG) has a market capitalization of $7.03M.
In fiscal 2025, FBLG reported revenue of $0.00.
FBLG Stock Return by Calendar Year
FibroBiologics, Inc. (FBLG) return since Jan 2024: what $10,000 became
- 1 year
- $10,000 $1,188
- −88.12%
- Since Jan 2024
- $10,000 $17
- −99.83%
If you had invested $10,000 in FibroBiologics, Inc. (FBLG) at the close on January 31, 2024, the earliest close on record here, it would have been worth $17 at the close on October 21, 2026: −99.83% in total, −90.39% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −77.93% |
| 2025 | −88.75% |
| 2024 | −93.13% |
As of October 21, 2026.
FBLG Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$18.65M | — |
| 2024 | $0.00 | −$11.16M | — |
| 2023 | $0.00 | −$16.49M | — |
| 2022 | $0.00 | −$5.12M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$16.65M | −$18.65M | — |
| 2024 | $0.00 | — | −$13.74M | −$11.16M | — |
| 2023 | $0.00 | — | −$8.89M | −$16.49M | — |
| 2022 | $0.00 | — | −$4.47M | −$5.12M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
YahooFibroBiologics Reports Preclinical Data Showing FSdC Spheroids Best Preserve Disc Height In Rabbit Degenerative Disc Disease Model
BenzingaFibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
YahooFibroBiologics Says IP Australia Issues Notice Of Acceptance For Australian Patent Application Titled ‘Cellular Blend For The Regeneration Of Chondrocytes Or Cartilage Type Cells’
BenzingaFibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
YahooEXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections
Yahoo
All 20 articles ↓Show fewer ↑
FibroBiologics Files U.S. Patent Application For New Cell-Based Technology Designed To Continuously Produce Peptides Such As GLP-1, GIP and GLP-2 In The Body
BenzingaFibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
YahooFibroBiologics Receives European Patent Titled Methods Of Enhancing Fibroblast Therapeutic Activity
BenzingaNova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
YahooFibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
SeekingAlphaFibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
YahooFibroBiologics Completes ATM Private Placement Of 298,508 Shares And Warrants At $1.675 Per Unit To Its Chief Scientific Officer
BenzingaJoin FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
YahooFibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
YahooFibroBiologics Secures US Patent For Therapeutic Use Of Fibroblasts For Use In Wound Healing
BenzingaFibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
YahooFibroBiologics Receives Patent From United States Patent And Trademark Office Titled 'Treatment Of Disc Degenerative Disease And Stimulation Of Proteoglycan Synthesis By Fibroblast Conditioned Media And Formulations Thereof'
BenzingaFibroBiologics Releases Third cGMP CYWC628 Drug Product Batch For Shipment To Australia, Supporting Ongoing Phase 1/2 Diabetic Foot Ulcer Trial
BenzingaFibroBiologics Regains Nasdaq Compliance
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B